News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abraxis BioScience, Inc. Release: American Society of Clinical Oncology Presentations Offer New Insights into Role of nab(R)-Chemotherapy Based Breast Cancer Chemotherapy Treatment


6/8/2010 9:41:32 AM

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII) presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Studies included three ongoing trials of nab-paclitaxel in the treatment of triple-negative breast cancer (TNBC), HER2-negative primary operable breast cancer, and elderly patients with an increased risk for relapse of a primary carcinoma of the breast, continuing the company’s focus on developing treatments for difficult-to-treat cancers.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES